IJCS | Volume 33, Nº1, January / February 2019

48 Cont. Table 1 - Comparison of groups in relation to demographic, clinical, therapeutic, laboratory and outcome variables Variables Total LVEF p < 40% 40 – 49% ≥ 50% ACS-HF (%) 38.0 38.8 45.7 30.2 0.028* Comorbidities DM 50.7 44.9 58.1 52.7 0.050 SAH 87.2 82.7 93.8 88.0 0.011* IC 58.6 60.7 67.4 48.0 0.003* Valve disease 10.3 6.1 10.1 16.7 0.005* Kidney disease 34.5 36.0 34.9 32.0 0.729 COPD/Asma 19.5 21.0 17.1 19.3 0.666 Neoplasia 8.1 5.1 10.9 10.0 0.103 Alcoholism 18.3 22.4 20.2 10.7 0.014* Smoking 20.1 22.4 20.2 16.7 0.401 SBP (mmHg) – Mean (SD) 136.3 (31.8) 128.5 (27.9) +/++ 139.2 (31.9) 145.0 (34.4) < 0.001* HR (bpm) – Mean (SD) 87,4 (20.8) 87.9 (21.6) 88,4 (20.6) 85.9 (19.6) 0.557 AF (%) 22.8 20.5 19.7 28.8 0.144 EDD – Median (P25 – P75) 58 (50-65) 65 (58 - 70) +/++ 55 (52 – 62) +++ 47 (45 – 85) < 0.001* SPAP - Median (P25 – P75) 46 (39-57) 45 (40 – 56) 42 (37 – 56) 48 (42 – 59) 0.870 Moderate/severe MR (%) 47.9 55.2 56.1 30.3 < 0.001* Moderate/severe TR (%) 22.6 25.9 23.8 16.7 0.128 Increased RV (%) 19.6 30.2 12.9 11.0 < 0.001* LVEF – Mean (SD) 43.2 (14.3) 30.2 (6.6) 44.4 (2.7) 60.7 (7,3) - Sodium Ad – Mean (SD) 137.2 (5.8) 137.6 (5.5) 137.1 (5.9) 136.7 (6.2) 0.387 Urea Ad – Mean (SD) 64.9 (39.6) 68.5 (42.9) 64.7 (40.7) 60.1 (32.6) 0.141 Creatinine Ad – Mean (DP) 1.5 (0.9) 1.4 (0.8) 1.4 (0.9) 1.5 (1.1) 0.681 Hb Ad – Mean (SD) 12.2 (2.3) 12.6 (2.3) +/++ 11.9 (1.9) 11.8 (2.2) 0.002* BNP Ad Median (P 25 –P 75 ) 6,000 7,249 8,421 2,827 0.015* (2,769-15,927) (3,473-19,610) +/++ (5,304-22,352) +++ (1,685-6,285) B-blocker (%) 73.3 77.8 72.9 67.1 0.076 ACEi /ARB (%) 66.5 69.2 64.3 68.7 0.626 Digoxin (%) 22.0 28.6 17.2 16.8 0.008* SPIR (%) 41.7 52.8 38.8 28.2 < 0.001* In-hospital death (%) 14.0 18.2 12.4 12.0 0.173 Readmission within 30 d (%) 19.2 19.9 22.1 15.7 0.498 * Statistically significant (p < 0.05); + : Statistically significant difference between G1 (< 40%) and G2 (40-49%); ++ : Statistically significant difference between G1 (< 40%) and G3 (≥ 50%); +++ : Statistically significant difference between G2 (40-49%) and G3 (≥ 50%); A: p-value derived from ANOVA; χ : p-value derived from Pearson's Chi-Square test; K: p-value derived from Krukal-Wallis test. Cavalcanti et al. Decompensated heart failure with intermediate ejection fraction Int J Cardiovasc Sci. 2020;33(1):45-54 Original Article